Letter to the Editor
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virol. Mar 25, 2022; 11(2): 104-106
Published online Mar 25, 2022. doi: 10.5501/wjv.v11.i2.104
Therapeutic potential of N-acetyl cysteine during COVID-19 epoch
Ajita Kapur, Munish Sharma, Geetanjali Sageena
Ajita Kapur, Department of Pharmacology, V.P. Chest Institute, University of Delhi, Delhi 110007, India
Munish Sharma, Hindu Rao Hospital and NDMC Medical College, Delhi 110007, India
Geetanjali Sageena, Environmental Studies, Keshav Mahavidyalaya University of Delhi, New Delhi 110034, India
Author contributions: Kapur A designed the editorial; Kapur A, Sharma M, and Sageena G wrote the manuscript; All authors gave final approval for publication.
Conflict-of-interest statement: All authors declare no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Geetanjali Sageena, PhD, Assistant Professor, Environmental Studies, Keshav Mahavidyalaya University of Delhi, H-4-5 Zone Pitampura, New Delhi 110034, India. geetanjali.sageena@keshav.du.ac.in
Received: August 7, 2021
Peer-review started: August 7, 2021
First decision: November 11, 2021
Revised: November 22, 2021
Accepted: February 23, 2022
Article in press: February 23, 2022
Published online: March 25, 2022
Core Tip

Core Tip: Risk of coagulopathy is noteworthy in coronavirus disease 2019 (COVID-19) and cerebral hemorrhage could be a potential risk in COVID-19 patients receiving N-acetyl cysteine (NAC). Results of well-designed randomized controlled trials should be awaited before NAC becomes a common practice for prophylaxis and treatment of patients with COVID-19.